Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

5.550 -0.210 (-3.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutic Com

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Changes to Board of Directors
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
From Sage Therapeutics, Inc.
Via Business Wire
The Latest Analyst Ratings for Sage Therapeutics
Via Benzinga
Analyst Ratings for Sage Therapeutics
Via Benzinga
Why Sage Therapeutics Stock Sank Today
A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp. 
Via The Motley Fool
5 Biotech stocks tapping into unmet mental health treatment needs
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. 
Via MarketBeat
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Sage Therapeutics, Inc.
Via Business Wire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Biogen Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Sage Therapeutics
Via Benzinga
Where Sage Therapeutics Stands With Analysts
Via Benzinga
Sage Therapeutics to Present at Upcoming November Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse. 
Via InvestorPlace
Sage Therapeutics to Present at Upcoming September Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating DigitalOcean, and Sage and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Via ACCESSWIRE
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
The company is now focusing on its launch in postpartum depression. 
Via Investor's Business Daily
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
From Sage Therapeutics, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Blink, Lovesac, and Sage and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
3 Very Oversold Pharma Stocks to Buy Right Now
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy. 
Via InvestorPlace
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
The pharmaceutical company's growth prospects have taken a big hit. 
Via The Motley Fool
SAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Sage Therapeutics, Inc. on Behalf of Sage Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
SAGE INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.